Tissue-colonizing disseminated tumor cells secrete prostaglandin E2 to promote NK cell dysfunction and evade anti-metastatic immunity
Anna-Marie Pedde,
Hyunu Kim,
Sainitin Donakonda,
Tobias Baumann,
Felix Bayerl,
Philippa Meiser,
Anna Hirschberger,
Christine Klement,
Simon Grassmann,
Rupert Öllinger,
Norbert Hüser,
Daniel Hartmann,
Melanie Laschinger,
Joseph A. Trapani,
Alfred Zippelius,
Tobias Bald,
Gabriela M. Wiedemann,
Roland Rad,
Joseph C. Sun,
Bastian Höchst,
Jan P. Böttcher
Affiliations
Anna-Marie Pedde
Institute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany
Hyunu Kim
Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Sainitin Donakonda
Institute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany
Tobias Baumann
Institute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany
Felix Bayerl
Institute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany
Philippa Meiser
Institute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany
Anna Hirschberger
Institute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany
Christine Klement
Institute of Molecular Oncology and Functional Genomics, School of Medicine and Health, TUM, Munich, Germany
Simon Grassmann
Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Rupert Öllinger
Institute of Molecular Oncology and Functional Genomics, School of Medicine and Health, TUM, Munich, Germany
Norbert Hüser
Department of Surgery, School of Medicine and Health, TUM, Munich, Germany
Daniel Hartmann
Department of Surgery, School of Medicine and Health, TUM, Munich, Germany; Department of Surgery, University Clinic Tübingen, M3 Research Center, Tübingen, Germany
Melanie Laschinger
Department of Surgery, School of Medicine and Health, TUM, Munich, Germany
Joseph A. Trapani
Cancer Immunology Program, Peter MacCallum Cancer Centre, 305 Grattan St., Melbourne, VIC, Australia
Alfred Zippelius
Cancer Immunology, Department of Biomedicine, University and University Hospital Basel, Basel, Switzerland
Tobias Bald
Institute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn, Germany
Gabriela M. Wiedemann
Department of Internal Medicine II, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany
Roland Rad
Institute of Molecular Oncology and Functional Genomics, School of Medicine and Health, TUM, Munich, Germany
Joseph C. Sun
Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Bastian Höchst
Institute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany
Jan P. Böttcher
Institute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany; Corresponding author
Summary: Natural killer (NK) cells are critical for anti-metastatic immunity and can eliminate metastasizing tumor cells within circulation and sites of metastatic seeding. Here, we show that disseminated tumor cells (DTCs) colonizing the mouse lung secrete prostaglandin E2 (PGE2) to locally induce NK cell dysfunction, allowing outgrowing metastases to escape immune control and establish metastatic disease. Mechanistically, PGE2 signaling through its receptors EP2 and EP4 mediates NK cell dysfunction, which leads to reprogramming of NK cell gene expression and results in impaired production of anti-metastatic cytokines. In human cancer patients, the PGE2-EP2/EP4 axis is associated with NK cell dysfunction within distant organ metastases. Disabling EP2/EP4 signaling in NK cells prevents their dysfunction in DTC-colonized lungs and achieves effective NK cell-mediated control of metastatic disease. Our findings reveal a suppressive signaling axis exploited by metastasizing tumor cells to escape immune control in distant organs that could be targeted for metastatic cancer therapy.